Juan F Iglesias1, Sophie Degrauwe1, Fabio Rigamonti1, Stéphane Noble1, Marco Roffi2. 1. Division of Cardiology, Geneva University Hospitals, Rue Gabrielle Perret-Gentil 4, 1211, Geneva 14, Switzerland. 2. Division of Cardiology, Geneva University Hospitals, Rue Gabrielle Perret-Gentil 4, 1211, Geneva 14, Switzerland. marco.roffi@hcuge.ch.
Abstract
PURPOSE OF REVIEW: Diabetes mellitus (DM) is highly prevalent among patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs). This review aims to summarize the available evidence on CTO recanalization in patients with DM. RECENT FINDINGS: Coronary artery bypass grafting (CABG) surgery is the recommended revascularization modality for patients with DM and multivessel coronary artery disease (CAD). However, the optimal management strategy in diabetic patients with CTO and single-vessel disease or prior CABG remains a clinical dilemma. Contemporary, large-scale, observational registries support the notion that CTO PCI, if performed at high-volume CTO PCI centers by highly experienced operators, conveys similar high procedural success and low complication rates in patients with and without DM. Although DM patients have more frequently CTOs and may derive greater benefit from complete revascularization, they are less frequently exposed to CTO PCI than non-DM patients (treatment-risk paradox). CTO PCI performed by highly experienced operators constitutes a safe and effective treatment option for selected diabetic CTO patients who are not candidates for CABG. Randomized studies are warranted to compare long-term outcomes of CTO PCI and medical therapy in this high-risk subset.
PURPOSE OF REVIEW: Diabetes mellitus (DM) is highly prevalent among patients undergoing percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs). This review aims to summarize the available evidence on CTO recanalization in patients with DM. RECENT FINDINGS: Coronary artery bypass grafting (CABG) surgery is the recommended revascularization modality for patients with DM and multivessel coronary artery disease (CAD). However, the optimal management strategy in diabeticpatients with CTO and single-vessel disease or prior CABG remains a clinical dilemma. Contemporary, large-scale, observational registries support the notion that CTO PCI, if performed at high-volume CTO PCI centers by highly experienced operators, conveys similar high procedural success and low complication rates in patients with and without DM. Although DMpatients have more frequently CTOs and may derive greater benefit from complete revascularization, they are less frequently exposed to CTO PCI than non-DMpatients (treatment-risk paradox). CTO PCI performed by highly experienced operators constitutes a safe and effective treatment option for selected diabetic CTO patients who are not candidates for CABG. Randomized studies are warranted to compare long-term outcomes of CTO PCI and medical therapy in this high-risk subset.
Authors: Vasim Farooq; Patrick W Serruys; Christos V Bourantas; Yaojun Zhang; Takashi Muramatsu; Ted Feldman; David R Holmes; Michael Mack; Marie Claude Morice; Elisabeth Ståhle; Antonio Colombo; Ton de Vries; Marie-angèle Morel; Keith D Dawkins; Arie-Pieter Kappetein; Friedrich W Mohr Journal: Circulation Date: 2013-06-13 Impact factor: 29.690
Authors: Arie Pieter Kappetein; Stuart J Head; Marie-Claude Morice; Adrian P Banning; Patrick W Serruys; Friedrich-Wilhelm Mohr; Keith D Dawkins; Michael J Mack Journal: Eur J Cardiothorac Surg Date: 2013-02-14 Impact factor: 4.191
Authors: Stuart J Head; Milan Milojevic; Joost Daemen; Jung-Min Ahn; Eric Boersma; Evald H Christiansen; Michael J Domanski; Michael E Farkouh; Marcus Flather; Valentin Fuster; Mark A Hlatky; Niels R Holm; Whady A Hueb; Masoor Kamalesh; Young-Hak Kim; Timo Mäkikallio; Friedrich W Mohr; Grigorios Papageorgiou; Seung-Jung Park; Alfredo E Rodriguez; Joseph F Sabik; Rodney H Stables; Gregg W Stone; Patrick W Serruys; Arie Pieter Kappetein Journal: Lancet Date: 2018-02-23 Impact factor: 79.321